These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 25614132)

  • 21. Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.
    Poels EM; Kegeles LS; Kantrowitz JT; Javitt DC; Lieberman JA; Abi-Dargham A; Girgis RR
    Schizophr Res; 2014 Feb; 152(2-3):325-32. PubMed ID: 24418122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proton magnetic resonance spectroscopy of the human brain in schizophrenia.
    Deicken RF; Johnson C; Pegues M
    Rev Neurosci; 2000; 11(2-3):147-58. PubMed ID: 10718151
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies.
    Kegeles LS; Shungu DC; Anjilvel S; Chan S; Ellis SP; Xanthopoulos E; Malaspina D; Gorman JM; Mann JJ; Laruelle M; Kaufmann CA
    Psychiatry Res; 2000 May; 98(3):163-75. PubMed ID: 10821999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In Vivo
    Mandal PK; Guha Roy R; Samkaria A; Maroon JC; Arora Y
    Neurochem Res; 2022 May; 47(5):1183-1201. PubMed ID: 35089504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Imaging central neurochemical alterations in chronic pain with proton magnetic resonance spectroscopy.
    Harris RE; Clauw DJ
    Neurosci Lett; 2012 Jun; 520(2):192-6. PubMed ID: 22445845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proton magnetic resonance spectroscopy study of brain metabolite changes after antipsychotic treatment.
    Szulc A; Galinska B; Tarasow E; Waszkiewicz N; Konarzewska B; Poplawska R; Bibulowicz D; Simonienko K; Walecki J
    Pharmacopsychiatry; 2011 Jun; 44(4):148-57. PubMed ID: 21710405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disrupted GABAergic facilitation of working memory performance in people with schizophrenia.
    Ragland JD; Maddock RJ; Hurtado MY; Tanase C; Lesh TA; Niendam TA; Carter CS; Ranganath C
    Neuroimage Clin; 2020; 25():102127. PubMed ID: 31864216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced
    Wang J; Tang Y; Zhang T; Cui H; Xu L; Zeng B; Li Y; Li G; Li C; Liu H; Lu Z; Zhang J; Wang J
    Neural Plast; 2016; 2016():3915703. PubMed ID: 28003912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [To Test Glutamate Hypothesis for Schizophrenia Utilizing Proton Magnetic Resonance Spectroscopy].
    Tsugawa S; Nakajima SL
    Brain Nerve; 2017 Sep; 69(9):1035-1040. PubMed ID: 28900066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cortico-Striatal GABAergic and Glutamatergic Dysregulations in Subjects at Ultra-High Risk for Psychosis Investigated with Proton Magnetic Resonance Spectroscopy.
    de la Fuente-Sandoval C; Reyes-Madrigal F; Mao X; León-Ortiz P; Rodríguez-Mayoral O; Solís-Vivanco R; Favila R; Graff-Guerrero A; Shungu DC
    Int J Neuropsychopharmacol; 2015 Sep; 19(3):pyv105. PubMed ID: 26364273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Magnetic resonance spectroscopy in schizophrenia. Possibilities and limitations].
    Wobrock T; Scherk H; Falkai P
    Radiologe; 2005 Feb; 45(2):124-30, 132-6. PubMed ID: 15645203
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proton magnetic resonance spectroscopy changes after antipsychotic treatment.
    Szulc A; Galinska-Skok B; Waszkiewicz N; Bibulowicz D; Konarzewska B; Tarasow E
    Curr Med Chem; 2013; 20(3):414-27. PubMed ID: 23157634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abnormal Concentration of GABA and Glutamate in The Prefrontal Cortex in Schizophrenia.-An in Vivo 1H-MRS Study.
    Chen T; Wang Y; Zhang J; Wang Z; Xu J; Li Y; Yang Z; Liu D
    Shanghai Arch Psychiatry; 2017 Oct; 29(5):277-286. PubMed ID: 29276351
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of proton magnetic resonance spectroscopy in the treatment of psychiatric disorders: a critical update.
    Bustillo JR
    Dialogues Clin Neurosci; 2013 Sep; 15(3):329-37. PubMed ID: 24174904
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamatergic and GABAergic metabolite levels in schizophrenia-spectrum disorders: a meta-analysis of
    Nakahara T; Tsugawa S; Noda Y; Ueno F; Honda S; Kinjo M; Segawa H; Hondo N; Mori Y; Watanabe H; Nakahara K; Yoshida K; Wada M; Tarumi R; Iwata Y; Plitman E; Moriguchi S; de la Fuente-Sandoval C; Uchida H; Mimura M; Graff-Guerrero A; Nakajima S
    Mol Psychiatry; 2022 Jan; 27(1):744-757. PubMed ID: 34584230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perisylvian GABA levels in schizophrenia and bipolar disorder.
    Atagün Mİ; Şıkoğlu EM; Soykan Ç; Serdar Süleyman C; Ulusoy-Kaymak S; Çayköylü A; Algın O; Phillips ML; Öngür D; Moore CM
    Neurosci Lett; 2017 Jan; 637():70-74. PubMed ID: 27890741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.
    Reid MA; Salibi N; White DM; Gawne TJ; Denney TS; Lahti AC
    Schizophr Bull; 2019 Jan; 45(1):180-189. PubMed ID: 29385594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Advances in neuroimaging in schizophrenia: magnetic resonance spectroscopy].
    Galińska B; Szulc A; Walecki J; Kubas B; Tarasów E
    Pol Merkur Lekarski; 2003 Sep; 15(87):278-80. PubMed ID: 14679857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proton magnetic resonance spectroscopy as a probe into the pathophysiology of autism spectrum disorders (ASD): a review.
    Baruth JM; Wall CA; Patterson MC; Port JD
    Autism Res; 2013 Apr; 6(2):119-33. PubMed ID: 23436782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proton magnetic resonance spectroscopy and its diagnostically important metabolites in the brain.
    Bittšanský M; Výbohová D; Dobrota D
    Gen Physiol Biophys; 2012 Mar; 31(1):101-12. PubMed ID: 22447836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.